The Bucharest Sector 5 Court turned down on Saturday the request of the General Prosecution Office to have managing director of drug maker Hexi Pharma placed under pre-trial arrest, ordering her under house arrest instead.
The decision is not final, but Dinu will be released from police custody upon the expiry of the 24-hour arrest warrant issued for her on Friday.
The Criminal and Forensic Investigation Section of the Prosecutor’s Office attached to the High Court of Cassation and Justice remanded Dinu Friday night on 99 counts of repeated deceptive activities and 29 counts of deception and participation in forestalling disease combat, referring her to court for a proposed 30-day pre-trial arrest.
Prosecutors accuse Hexi Pharma managing director Flori Dinu of acting to ramp up sales of non-compliant products
The General Prosecution Office asserts that the Hexi Pharma managing director, who was mainly responsible for the company’s sales activity, acting at the instigation of company owner Dan Condrea and knowing that the products do not meet the specifications of the labels, coordinated the entire staff involved in the promotion of the products and mediated the negotiation and conclusion of supply contracts, misleading the representatives of medical facilities that purchased the products. The crimes were perpetrated by fraudulent means, represented by the labels of the non-compliant products and the offers sent to the deceived companies, directly or through the portal e-licitatii.ro, the General Prosecution Office informs in a release. The damage incurred on the injured entities is in excess of 28 million lei, representing the non-compliant products supplied under contracts concluded between June 2012 – April 2016 by the company under suspicion and numerous health care facilities.
In the same case, the prosecutors ordered the expansion of the scope of prosecution against Hexi Pharma head of production Mihai Leva, for repeatedly aiding and abetting the forestalling of disease combat; Leva is currently under court restriction.
The General Prosecution Office said the damage incurred on the injured entities is in excess of 28 million lei, representing the non-compliant products supplied under contracts concluded between June 2012 – April 2016 by the company under suspicion and numerous health care facilities.
The evidence produced up until now has revealed that defendant Flori Dinu, responsible for managing and coordinating the Hexi Pharma sales department and for ensuring the sale, to several health care facilities, of products she knew were sub-standard, has forestalled through such activities in the respective period measures by the injured parties to prevent and combat infectious diseases, which resulted in the spread of thereof, the prosecutors note.